Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model
Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease that mainly affects the spinal cord and optic nerve, causing blindness and paralysis in some individuals. Moreover, NMO may cause secondary complement-dependent cytotoxicity (CDC), leading to oligodendrocyte and neuronal...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2018/4187347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549426845974528 |
|---|---|
| author | Yuanyuan Zhang Kewei Tian Hong Jiang Beibei Wang Shu Han |
| author_facet | Yuanyuan Zhang Kewei Tian Hong Jiang Beibei Wang Shu Han |
| author_sort | Yuanyuan Zhang |
| collection | DOAJ |
| description | Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease that mainly affects the spinal cord and optic nerve, causing blindness and paralysis in some individuals. Moreover, NMO may cause secondary complement-dependent cytotoxicity (CDC), leading to oligodendrocyte and neuronal damage. In this study, a rodent NMO model, showing typical NMO pathogenesis, was induced with NMO-IgG from patient serum and human complement. We then tested whether the combination of C16, an αvβ3 integrin-binding peptide, and angiopoietin-1 (Ang1), a member of the endothelial growth factor family, could alleviate NMO in the model. Our results demonstrated that this combination therapy significantly decreased disease severity, inflammatory cell infiltration, secondary demyelination, and axonal loss, thus reducing neural death. In conclusion, our study suggests a possible treatment that can relieve progressive blindness and paralysis in an animal model of NMO through improvement of the inflammatory milieu. |
| format | Article |
| id | doaj-art-2b3ca3e5f0a244b6af09433514d0ac12 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-2b3ca3e5f0a244b6af09433514d0ac122025-02-03T06:11:16ZengWileyMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/41873474187347Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental ModelYuanyuan Zhang0Kewei Tian1Hong Jiang2Beibei Wang3Shu Han4Institute of Anatomy and Cell Biology, Medical College, Zhejiang University, Hangzhou, ChinaInstitute of Anatomy and Cell Biology, Medical College, Zhejiang University, Hangzhou, ChinaDepartment of Electrophysiology, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Hangzhou, ChinaCore Facilities, Zhejiang University School of Medicine, Hangzhou, ChinaInstitute of Anatomy and Cell Biology, Medical College, Zhejiang University, Hangzhou, ChinaNeuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease that mainly affects the spinal cord and optic nerve, causing blindness and paralysis in some individuals. Moreover, NMO may cause secondary complement-dependent cytotoxicity (CDC), leading to oligodendrocyte and neuronal damage. In this study, a rodent NMO model, showing typical NMO pathogenesis, was induced with NMO-IgG from patient serum and human complement. We then tested whether the combination of C16, an αvβ3 integrin-binding peptide, and angiopoietin-1 (Ang1), a member of the endothelial growth factor family, could alleviate NMO in the model. Our results demonstrated that this combination therapy significantly decreased disease severity, inflammatory cell infiltration, secondary demyelination, and axonal loss, thus reducing neural death. In conclusion, our study suggests a possible treatment that can relieve progressive blindness and paralysis in an animal model of NMO through improvement of the inflammatory milieu.http://dx.doi.org/10.1155/2018/4187347 |
| spellingShingle | Yuanyuan Zhang Kewei Tian Hong Jiang Beibei Wang Shu Han Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model Mediators of Inflammation |
| title | Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model |
| title_full | Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model |
| title_fullStr | Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model |
| title_full_unstemmed | Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model |
| title_short | Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model |
| title_sort | combination treatment of c16 peptide and angiopoietin 1 alleviates neuromyelitis optica in an experimental model |
| url | http://dx.doi.org/10.1155/2018/4187347 |
| work_keys_str_mv | AT yuanyuanzhang combinationtreatmentofc16peptideandangiopoietin1alleviatesneuromyelitisopticainanexperimentalmodel AT keweitian combinationtreatmentofc16peptideandangiopoietin1alleviatesneuromyelitisopticainanexperimentalmodel AT hongjiang combinationtreatmentofc16peptideandangiopoietin1alleviatesneuromyelitisopticainanexperimentalmodel AT beibeiwang combinationtreatmentofc16peptideandangiopoietin1alleviatesneuromyelitisopticainanexperimentalmodel AT shuhan combinationtreatmentofc16peptideandangiopoietin1alleviatesneuromyelitisopticainanexperimentalmodel |